37: 923, doi: Koozehchian MS, Daneshfar A, Fallah E, Agha-Alinejad H, Samadi M, Kaviani M, Kaveh BM, Jung YP, Sablouei MH, Moradi N, Earnest CP, Chandler TJ, Kreider RB
For Saxenda, treatment should be discontinued if less than 5% weight loss is achieved after 12 weeks at the 3 mg daily dose
Materials and methods Two large-scale human studies Study samples and designs Cross-sectional clinical study The study population comprised three distinct groups: 78 individuals with ongoing PTSD ( persistent PTSD group ), 84 individuals who had previously been diagnosed with PTSD but had recovered ( recovered PTSD group ), and 86 healthy individuals who had no exposure to an index trauma ( healthy control group )
The association of reduction in cardiovascular risk with treatment-induced reductions in LDL cholesterol is recognized [30, 31], and the above studies of peptide-based GLP-1 RAs demonstrate reductions in total and LDL cholesterol concentrations in association with improved CV risk